Recent studies indicate that binding and neutralizing SARS-CoV-2 antibodies elicited by natural infection or vaccination persist for more than 6 months although their concentration decreases over time.
1The passive transfer of neutralizing antibodies (NAb) and protection are correlated in non-human primates.
- Doria-Rose N.
- Suthar M.S.
- Makowski M.
- O'Connell S.
- McDermott A.B.
- Flach B.
- et al.
Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for COVID-19.
N Engl J Med. 2021; 384: 2259-2261https://doi.org/10.1056/NEJMc2103916
2While such a link has not yet been defined in humans, individuals with a high NAb titer could well be better protected against SARS-CoV-2. A recent letter in Journal of Infection indicated that indeed neutralizing antibodies are considered linked to protective immunity due to their ability to block the viruses from entering the host cells. The authors discussed the decrease in neutralizing antibodies after vaccination without being able to provide a threshold below which protection against SARS-CoV-2 infection is no longer guaranteed.
- McMahan K.
- Yu J.
- Mercado N.B.
- Loos C.
- Tostanoski L.H.
- Chandrashekar A.
- et al.
Correlates of protection against SARS-CoV-2 in rhesus macaques.
Nature. 2021; 590: 630-634https://doi.org/10.1038/s41586-020-03041-6
- Douxfils J.
- Gillot C.
- Mullier F.
- Favresse J.
Post-SARS-CoV-2 vaccination specific antibody decrease - thresholds for determining seroprevalence and seroneutralization differ.
J Infect. 2021; S0163-4453 ([published online ahead of print]): 00405-00409https://doi.org/10.1016/j.jinf.2021.08.023
We measured the antibody titers in 8758 healthcare workers (HCWs), vaccinated and unvaccinated, soon after the first epidemic wave had occurred in France (10 June–10 July, 2020). Total SARS-CoV-2 antibodies were measured in longitudinal samples
with a quantitative enzyme-linked immunosorbent assay (ELISA) (Wantai Biological Pharmacy Enterprise Co., Ltd, China) and a live-virus neutralization assay using Vero cells and a B.1.160 strain (GISAID EPI-ISL-804372).
4Symptomatic and asymptomatic infections were detected with a nucleic-acid amplification method (AptimaTM SARS-CoV-2 assay, PantherTM system, Hologic, USA).
- Dimeglio C.
- Herin F.
- Miedougé M.
- Cambus J.P.
- Abravanel F.
- Mansuy J.M.
- et al.
Screening for SARS-CoV-2 antibodies among healthcare workers in a university hospital in southern France.
J Infect. 2020; 82: e29-e32https://doi.org/10.1016/j.jinf.2020.09.035
5This study was approved by the French Research Ethics Committee Est-III (COVID BioToul, ID-RCB 2020-A01292-37, ClinicalTrials.gov Identifier: NCT04385108).
- Trémeaux P.
- Lhomme S.
- Abravanel F.
- Raymond S
- Mengelle C.
- Mansuy J.M.
- et al.
Evaluation of the Aptima™ transcription-mediated amplification assay (HologicⓇ) for detecting SARS-CoV-2 in clinical specimens.
J Clin Virol. 2020; 129104541https://doi.org/10.1016/j.jcv.2020.104541
The median age of the 8758 HCWs (7039; 80.4% females) was 40 years (interquartile range [IQR] 32–50). Over half of them (4811; 54.9%) had been given one (2244; 46.6%) or two (2567; 53.4%) doses of vaccine between January and April 15, 2021. Of these, 1290 (26.8%) had one dose of the Oxford–AstraZeneca ChAdOx1 nCoV-19 (AZD1222) vaccine, 954 (19.8%) had one dose of the Pfizer-BioNTech COVID-19 mRNA (BNT162b2) vaccine and 2567 (53.4%) had two doses. An average of 9.65% (range [7.2–12.1%]) of the HCW who had no NAbs became infected after a median follow-up of 275 days (IQR: 265–281), as did 2.2% [95% CI: 0.4–4%] of those with a NAb titer well below 64. In contrast only 0.6% [95% CI: 0–1.5%] of those with NAb titers of 64 to 128 became infected together with none of those with NAb titers of 256 and above (Fig. 1, p < 0.01, Chi2 test). The correlation between the ELISA total antibody values expressed in binding antibody units (BAU) per ml using the WHO international standard (NIBSC code 20/136)
6and the neutralizing antibody titers from July 2020 to April 2021 was 0.8 for unvaccinated HCWs and 0.79 for vaccinated HCWs. Analysis of ELISA total antibody concentrations indicated that 12.1% [95% CI: 11.5–12.8%] of HCWs with a negative ELISA or an ELISA concentration below 13 BAU/ml became infected between July 2020 and April 2021, as did 10.6% [95% CI: 6.5–16.1%] of HCWs that had an ELISA concentration between 13 and 141 BAU/ml. In contrast only 1.3% [95% CI: 0.03–7.2%] of those with an ELISA concentration between 141 and 1700 BAU/ml became infected and none of those with an ELISA concentration of 1700 BAU/ml and above (p < 0.01, Chi2 test). Analysis of all the data indicated that a NAb titer well below 64 provided 76.8% protection against SARS-CoV-2, a titer of 64 to 128 gave 94% protection and a NAb titer of 256 or more provided full (100%) protection (Fig. 2A). In the same way, an ELISA concentration between 13 and 141 BAU/ml provided only 12.4% protection against SARS-CoV-2, a concentration between 141 and 1700 BAU/ml provided 89.3% protection and a concentration of 1700 BAU/ml and above provided full protection (Fig. 2B). In our cohort, none of the two doses-vaccinated HCWs had an ELISA concentration below 141 BAU/ml one month after the second injection, unlike 79.3% of the HCWs three months after a natural infection.
- Kumar A.
- Bernasconi V.
- Manak M.
- de Almeida Aranha A.P.
- Kristiansen P.A.
The CEPI centralised laboratory network: supporting COVID-19 vaccine development.
Lancet. 2021; 397: 2148-2149https://doi.org/10.1016/S0140-6736(21)00982-X
Our study did not assess cell-mediated immunity and all the subjects were HCWs. However, the data suggest that monitoring the neutralizing antibody response but also total antibody concentrations, logistically more feasible, can be used to optimize vaccination strategies by estimating the duration and degree of protection provided by vaccines. The thresholds of protection found in our study should be compared to those obtained in further studies on other populations. It is also essential to estimate the influence of an antibody's reduced neutralizing capacity against new emerging viruses variants [
- Planas D.
- Veyer D.
- Baidaliuk A.
- Staropoli I.
- Guivel-Benhassine F.
- Rajah M.M.
- et al.
Reduced sensitivity of SARS-CoV-2 variant delta to antibody neutralization.
Nature. 2021; 596: 276-280https://doi.org/10.1038/s41586-021-03777-9
- Wall E.C.
- Wu M.
- Harvey R.
- Kelly G.
- Warchal S.
- Sawyer C.
- et al.
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination.
Lancet. 2021; 397: 2331-2333https://doi.org/10.1016/S0140-6736(21)01290-3
No specific funding
Declaration of Competing Interest
The authors declare no conflict of interest
The English text was edited by Dr Owen Parkes.
- Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for COVID-19.N Engl J Med. 2021; 384: 2259-2261https://doi.org/10.1056/NEJMc2103916
- Correlates of protection against SARS-CoV-2 in rhesus macaques.Nature. 2021; 590: 630-634https://doi.org/10.1038/s41586-020-03041-6
- Post-SARS-CoV-2 vaccination specific antibody decrease - thresholds for determining seroprevalence and seroneutralization differ.J Infect. 2021; S0163-4453 ([published online ahead of print]): 00405-00409https://doi.org/10.1016/j.jinf.2021.08.023
- Screening for SARS-CoV-2 antibodies among healthcare workers in a university hospital in southern France.J Infect. 2020; 82: e29-e32https://doi.org/10.1016/j.jinf.2020.09.035
- Evaluation of the Aptima™ transcription-mediated amplification assay (HologicⓇ) for detecting SARS-CoV-2 in clinical specimens.J Clin Virol. 2020; 129104541https://doi.org/10.1016/j.jcv.2020.104541
- The CEPI centralised laboratory network: supporting COVID-19 vaccine development.Lancet. 2021; 397: 2148-2149https://doi.org/10.1016/S0140-6736(21)00982-X
- Reduced sensitivity of SARS-CoV-2 variant delta to antibody neutralization.Nature. 2021; 596: 276-280https://doi.org/10.1038/s41586-021-03777-9
- Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination.Lancet. 2021; 397: 2331-2333https://doi.org/10.1016/S0140-6736(21)01290-3
Published online: September 20, 2021
Accepted: September 16, 2021
© 2021 The British Infection Association. Published by Elsevier Ltd. All rights reserved.